Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC

Rearrangements of the anaplastic lymphoma kinase ( ALK ) gene were first identified in 2007 and occur in 3 to 5% of all patients with advanced non-small cell lung cancer (NSCLC) (1).